Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Macular Degeneration: HELP
Articles by Q. D. Nguyen
Based on 7 articles published since 2010
(Why 7 articles?)
||||

Between 2010 and 2020, Q. D. Nguyen wrote the following 7 articles about Macular Degeneration.
 
+ Citations + Abstracts
1 Clinical Trial Association of retinal vessel calibre and visual outcome in eyes with diabetic macular oedema treated with ranibizumab. 2014

Moradi, A / Sepah, Y J / Ibrahim, M A / Sophie, R / Moazez, C / Bittencourt, M G / Annam, R E / Hanout, M / Liu, H / Ferraz, D / Do, D V / Nguyen, Q D / Anonymous960804. ·Retinal Imaging Research and Reading Centre, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA. · 1] Retinal Imaging Research and Reading Centre, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA [2] Ocular Imaging Research and Reading Centre, Stanley M. Truhlsen Eye Institute, University of Nebraska Medical Centre, Omaha, NE, USA. · Ocular Imaging Research and Reading Centre, Stanley M. Truhlsen Eye Institute, University of Nebraska Medical Centre, Omaha, NE, USA. ·Eye (Lond) · Pubmed #25145456.

ABSTRACT: PURPOSE: The study aims to identify the association between the baseline retinal vascular calibre and visual outcome of patients with diabetic macular oedema (DMO) treated with intravitreal ranibizumab. METHODS: The 1-M field (as defined in the ETDRS study) of the digital colour fundus photographs of DMO patients who had been treated primarily with ranibizumab in a clinical trial was assessed. Of the 84 patients, 25 had gradable retinal photographs that could be subjected to analyses by the Interactive Vessel Analysis (IVAN) software at baseline. The average retinal vascular calibre of the six largest venules (CRVE) and the six largest arterioles (CRAE) in the peripapillary area (0.5 and 1 disc diameter from the optic disc margin) was measured. The relationship between CRVE and CRAE at baseline and the change in visual acuity at month 12 was assessed using the Mann-Whitney U test. RESULTS: Ten eyes from 10 patients who had shown an improvement of ≥2 lines of best corrected visual acuity (BCVA) at month 12 had a wider baseline CRVE (248.3±24.5 μm) compared with the 15 eyes from 15 patients who did not show the improvement of ≥2 lines (226.6±44.8 μm, P<0.05). The baseline CRAE did not differ significantly in these patients (156.1±22.7 vs 142±17.5 μm, P=0.17). CONCLUSIONS: A wider baseline retinal venular calibre may be a predictor of better visual outcome in DMO eyes treated with ranibizumab. Further prospective studies with a larger sample size and a broader range of disease severity and visual acuity are needed to confirm this finding.

2 Clinical Trial Phase 1 dose-escalation study of a siRNA targeting the RTP801 gene in age-related macular degeneration patients. 2012

Nguyen, Q D / Schachar, R A / Nduaka, C I / Sperling, M / Basile, A S / Klamerus, K J / Chi-Burris, K / Yan, E / Paggiarino, D A / Rosenblatt, I / Khan, A / Aitchison, R / Erlich, S S / Anonymous720727. ·Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD, USA. ·Eye (Lond) · Pubmed #22627477.

ABSTRACT: BACKGROUND: To evaluate the safety, tolerability, pharmacokinetics, and dose-limiting toxicities of a single intravitreal (IVT) injection of PF-04523655, a 19-nucleotide, O-methyl stabilized, double-stranded small interfering ribonucleic acid targeting the RTP801 gene in patients with neovascular age-related macular degeneration (AMD). METHODS: Prospective, phase 1, clinical multicentre trial, enrolled 27 patients with neovascular AMD unresponsive to prior treatment and best corrected visual acuity (BCVA) ≤ 20/200 in the study eye in stratum 1: (dose-escalating, open-label: 50 to 3000 μg of PF-04523655) and 27 patients who had potential to benefit from therapy and BCVA of ≤ 20/100 and ≥ 20/800 in stratum 2 (parallel, masked study of 1000, 1500, 2250, and 3000 μg of PF-04523655). The primary outcome was safety and tolerability assessment as well as pharmacokinetic profiling following a single IVT injection of PF-04523655. RESULTS: Doses of PF-04523655 ≥ 400 μg were generally detectable in the plasma at 1, 4, and 24 h post-injection. And all doses were below the lowest level of quantification by day 14. A single IVT injection of 50 to 3000 μg of PF-045237655 was generally safe and well tolerated over 24 months. There were no dose-limiting toxicities. CONCLUSION: A single IVT injection of PF-0523655 ≤ 3000 μg seems safe and well tolerated in eyes with neovascular AMD.

3 Clinical Trial Safety, tolerability, and bioavailability of topical SAR 1118, a novel antagonist of lymphocyte function-associated antigen-1: a phase 1b study. 2012

Paskowitz, D M / Nguyen, Q D / Gehlbach, P / Handa, J T / Solomon, S / Stark, W / Shaikh, O / Semba, C / Gadek, T R / Do, D V. ·Wilmer Eye Institute, Johns Hopkins University, 600 North Wolfe Street, Baltimore, MD 21287, USA. ·Eye (Lond) · Pubmed #22538219.

ABSTRACT: PURPOSE: A growing body of evidence points to a role for inflammation mediated by lymphocyte function-associated antigen-1 (LFA-1) and its ligand intercellular adhesion molecule-1 in the pathogenesis of diabetic macular oedema. This phase 1b clinical trial assessed the safety, tolerability, and pharmacokinetics of topically administered SAR 1118, a novel LFA-1 antagonist, in human subjects. METHODS: In this prospective, randomized, double-masked trial, 13 subjects scheduled for vitrectomy received one of three concentrations of topical SAR 1118 (0.1, 1.0, or 5.0%) twice daily for 1 week before surgery. Undiluted aqueous and vitreous samples were collected at surgery and analysed for the concentration of the medication. RESULTS: All subjects completed the entire course of medication. The only adverse events reported were instillation site irritation (4/13, 31%) and dysgeusia (3/13, 23%). These were mild and transient, occurring at the highest dose. Mean concentrations (ng/ml) of SAR 1118 in the aqueous humour were 0.25, 37.2, and 101.1 for the 0.1%, 1.0%, and 5.0% dose groups, respectively. SAR 1118 was below the level of detection (0.5 ng/ml) for all vitreous samples except in a single subject who had a history of prior vitrectomy and a dislocated intraocular lens. CONCLUSIONS: Topical SAR 1118 was safe and well tolerated, and dose-dependent levels of drug were detected in aqueous. However, vitreous levels were below the threshold of detection with the concentrations tested. Further investigation of this medication for posterior segment applications would require intravitreal delivery or chemical modification of the drug.

4 Article Month-6 primary outcomes of the READ-3 study (Ranibizumab for Edema of the mAcula in Diabetes-Protocol 3 with high dose). 2015

Do, D V / Sepah, Y J / Boyer, D / Callanan, D / Gallemore, R / Bennett, M / Marcus, D M / Halperin, L / Sadiq, M A / Rajagopalan, N / Campochiaro, P A / Nguyen, Q D / Anonymous1050838. ·Stanley M. Truhlsen Eye Institute, Carl Camras Center for Innovative Clinical Research, University of Nebraska Medical Center, Omaha, NE, USA. · Retina Vitreous Associates, Beverly Hills, CA, USA. · Texas Retina Associates, Arlington, TX, USA. · Retina Macula Institute, Torrance, CA, USA. · Retina Institute of Hawaii, Honolulu, HI, USA. · Southeast Retina Center, Augusta, GA, USA. · Retina Group of Florida, Fort Lauderdale, FL, USA. · Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD, USA. ·Eye (Lond) · Pubmed #26228291.

ABSTRACT: PURPOSE: To compare 2.0 mg ranibizumab (RBZ) injections with 0.5 mg RBZ for eyes with center-involved diabetic macular edema (DME) and a central subfield thickness (CFT) of ≥250 μm on time-domain optical coherence tomography.DesignRandomized, controlled, multicenter clinical trial. METHODS: Eligible eyes were randomized in a 1:1 ratio to 0.5 mg (n=77) or 2.0 mg (n=75) RBZ. Study eyes received 6-monthly injections.Main outcome measuresThe primary outcome measure was the mean change in best corrected visual acuity (BCVA) at month 6. Secondary outcomes included the incidence and severity of systemic and ocular adverse events and the mean change in CFT from baseline. RESULTS: In all, 152 eyes (152 patients) were randomized in the study. At month 6, the mean improvement from baseline BCVA was +9.43 letters in the 0.5 mg RBZ group and +7.01 letters in the 2.0 mg RBZ group (P=0.161). At month 6, one death occurred in the 0.5 mg RBZ group and three deaths in the 2.0 mg RBZ group, all due to myocardial infarction in subjects with a prior history of heart disease. Mean CFT was reduced by 168.58 μm in the 0.5 mg RBZ group and by 159.70 μm in the 2.0 mg RBZ group (P=0.708). CONCLUSIONS: There was no statistically significant difference in the mean number of letters gained between the 0.5 and 2.0 mg RBZ groups through month 6. In this DME study population, high-dose RBZ does not appear to provide additional benefit over 0.5 mg RBZ.

5 Article Longitudinal comparison of visual acuity as measured by the ETDRS chart and by the potential acuity meter in eyes with macular edema, and its relationship with retinal thickness and sensitivity. 2014

Hatef, E / Hanout, M / Moradi, A / Colantuoni, E / Bittencourt, M / Liu, H / Sepah, Y J / Ibrahim, M / Do, D V / Guyton, D L / Nguyen, Q D. ·1] Retinal Imaging Research and Reading Center, Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD, USA [2] General Preventive Medicine, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. · 1] Retinal Imaging Research and Reading Center, Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD, USA [2] Ocular Imaging Research and Reading Center, Stanley M. Truhlsen Eye Institute, University of Nebraska Medical Center, Omaha, NE, USA. · Retinal Imaging Research and Reading Center, Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD, USA. · Department of Biostatistics, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA. · Ocular Imaging Research and Reading Center, Stanley M. Truhlsen Eye Institute, University of Nebraska Medical Center, Omaha, NE, USA. ·Eye (Lond) · Pubmed #25104744.

ABSTRACT: PURPOSE: To evaluate the relationship between visual acuity as measured by the Early Treatment Diabetic Retinopathy Study (ETDRS) chart and by the potential acuity meter (PAM) with retinal thickness and sensitivity measured by a combined microperimetry/optical coherence tomography system (OCT). METHODS: Forty-four patients with macular edema (ME) were included in a prospective observational study. Visual acuity (VA) was assessed using the ETDRS chart (with best correction) as well as by the PAM. Retinal thickness and sensitivity was measured by an automatic fundus perimetry/tomography system. RESULTS: Best-corrected VA using the ETDRS chart ranged from 20/20 to 20/400 (median: 20/50). VA measured by the PAM without correction ranged from 20/20 to 20/400 (median: 20/40). The mean retinal thickness was 369.57 μm (s.d.: 140.28 μm) on spectral domain-OCT and the mean retinal sensitivity was 8.12 decibels (dB) (s.d.: 5.78 dB). The mean LogMAR value using the ETDRS chart was 0.43, whereas it was 0.38 using the PAM (P-value: 0.009). CONCLUSIONS: VA values measured by the PAM were statistically significantly better than those measured by the ETDRS chart in eyes with ME secondary to various retinal vascular and uveitic diseases. VA measured by the PAM may be a more sensitive predictor of macular function than that obtained by ETDRS testing in eyes with ME.

6 Article Factors affecting visual outcomes in patients with diabetic macular edema treated with ranibizumab. 2014

Channa, R / Sophie, R / Khwaja, A A / Do, D V / Hafiz, G / Nguyen, Q D / Campochiaro, P A / Anonymous3010776. ·The Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA. ·Eye (Lond) · Pubmed #24263379.

ABSTRACT: PURPOSE: To identify factors associated with visual outcomes in patients with diabetic macular edema (DME) treated with ranibizumab (RBZ) in the Ranibizumab for Edema of the mAcula in Diabetes-Protocol 2 (READ-2) Study. PATIENTS AND METHODS: Optical coherence tomography scans, fundus photographs, and fluorescein angiograms (FAs) were graded and along with baseline characteristics were correlated with month (M) 24 visual outcome of best-corrected visual acuity (BCVA) ≤20/100 (poor outcome) vs >20/100 (better outcome). RESULTS: Of 101 patients with a M20 visit or beyond, 27 (27%) had BCVA ≤20/100. Comparison of patients with or without poor outcome showed mean baseline BCVA of 16.8 letters (20/125) in the former compared with 30.4 letters (20/63; P<0.001). Mean change in BCVA between baseline and M24 was -2.6 letters in the poor outcome group compared with +9.8 letters (P<0.001). Foveal thickness (FTH) at M24 was 374.1 μm in the poor outcome group compared with 268.8 μm (P<0.01), a difference driven by 14 patients with mean FTH of 450.3 μm. Foveal atrophy occurred in 65% (11/17) in the poor outcome group compared with 17%(12/71, P=0.001). Persistent edema was noted in 52% (14/27) of patients with poor outcome. Laser scars near foveal center were significantly more common in patients with poor outcome who did not have edema vs those who did (78% (7/9) vs 23% (3/13) P=0.03). CONCLUSION: Poor baseline BCVA (≤20/125) in DME patients predicts poor visual outcome (≤20/100) after 2 years of treatment with RBZ and/or focal/grid laser, often due to foveal atrophy and/or persistent edema.

7 Article Spectral- and time-domain optical coherence tomography measurements of macular thickness in normal eyes and in eyes with diabetic macular edema. 2012

Ibrahim, M A / Sepah, Y J / Symons, R C A / Channa, R / Hatef, E / Khwaja, A / Bittencourt, M / Heo, J / Do, D V / Nguyen, Q D. ·Johns Hopkins University School of Medicine, Baltimore, MD, USA. ·Eye (Lond) · Pubmed #22134597.

ABSTRACT: PURPOSE: To report macular thickness values in normal eyes and eyes with diabetic macular edema (DME) using time-domain (TD) and spectral-domain (SD) optical coherence tomography (OCT), and to derive a conversion equation. METHODS: The index study was a prospective investigation conducted on 80 eyes from 40 normal subjects and 130 eyes from 118 patients with DME seen in our clinic. Retinal thickness values from the central 1 mm of the macula and surrounding four ETDRS subfields were acquired using TD-OCT (Stratus OCT) and SD-OCT (SPECTRALIS HRA+OCT). Measurements of the central (C) subfield from both devices were used to derive a conversion equation. The equation was used to predict SD-OCT values using measurements from TD-OCT. Agreement between predicted and actual SD-OCT measurements was assessed. RESULTS: In normal eyes, the mean difference between TD-OCT and SD-OCT measurements of the C subfield was 76 μm (CI(95)=74 and 77, respectively). The conversion equation, y=1.029x+72.49, was derived. In eyes with DME, using the equation, SPECTRALIS-predicted values were 5% higher than actual measurements, with 95% of predicted values falling within 9% of the actual measurements. Relocating SD-OCT grids to match the location on TD-OCT resulted in predicted values falling within 7% of actual measurements. CONCLUSIONS: The percent difference between actual thickness measurements from SPECTRALIS and predicted thickness measurements, using the conversion equation, was within reported limits of repeatability of Stratus in eyes with DME. Our equation may help correlate OCT values from both devices in standard care and clinical trials for DME.